Department of Surgery, Breast Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
Department of Medicine and Surgery, Plastic Surgery Division, University of Parma, Parma, Italy.
Breast J. 2020 Feb;26(2):247-251. doi: 10.1111/tbj.13541. Epub 2019 Sep 6.
Breast cancer is the most frequently diagnosed cancer in women in the western world and a major cause of premature death. Consequently, breast implants are widely used for breast reconstruction. Despite this, the prevalence of implant complications is low. Given widespread use of breast implants, there is an increased awareness of the risk for developing a breast implant associated- anaplastic large cell Lymphoma (BI-ALCL) although rare. Clinical presentation is variable and may include a palpable mass in the breast or axilla, generalized breast pain, or breast firmness. The estimated incidence of BI-ALCL is <3 per 1 million person years, approximately 0.1-0.3 per 100 000 women with prostheses per year. Since the publication by Keech and Creech in 1997, which reported the first case of BI-ALCL, an increasing number of BI-ALCL have appeared, in patients with both aesthetic and reconstructive indications. In this paper, we describe a patient who was diagnosed with invasive BIA-ALCL seventeen years after placement of silicone breast implants and was treated with only surgery.
在西方世界,乳腺癌是女性最常见的癌症,也是导致早逝的主要原因之一。因此,乳房植入物被广泛用于乳房重建。尽管如此,植入物并发症的发生率仍然很低。由于乳房植入物的广泛使用,人们越来越意识到发生与乳房植入物相关的间变性大细胞淋巴瘤(BI-ALCL)的风险,尽管这种情况很少见。临床表现多种多样,可能包括乳房或腋窝可触及的肿块、全身乳房疼痛或乳房硬结。BI-ALCL 的估计发病率为每 100 万人每年<3 例,每年每 10 万假体植入女性中约有 0.1-0.3 例。自 1997 年 Keech 和 Creech 发表报告首例 BI-ALCL 以来,越来越多的 BI-ALCL 出现在具有美容和重建指征的患者中。在本文中,我们描述了一名患者,她在放置硅胶乳房植入物十七年后被诊断为侵袭性 BIA-ALCL,仅接受了手术治疗。